Table 3.
Population parameter estimates from the PK model (bevacizumab analyzed alone) and TMDD model (bevacizumab and VEGF165 analyzed simultaneously)
| Parameter | PK model | TMDD model | ||
|---|---|---|---|---|
| Typical value (RSE %) | IIV, CV % (RSE %) | Typical value (RSE %) | IIV, CV % (RSE %) | |
| CL (L/day) | 0.17 (11) | 23 (23) | 0.18 (6) | 20 (25) |
| V 1 (L) | 3.14 (7) | 15 (38) | 3.23 (7) | 22 (36) |
| Q (L/day) | 0.36 (146) | 1.38 (19) | ||
| V 2 (L) | 2.63 (50) | 3.1 (18) | ||
| BM0 (ng/L) | 212 (8) | 33 (23) | ||
| k out (/day) | 0.401 (14) | |||
| K ss (nM) | 267 (22) | |||
| Prop. errorbev (%) | 24 (13) | 28 (15) | ||
| Prop. errorVEGF165 (%) | 32 (14) | |||
CL clearance, V 1 volume of central compartment, Q intercompartmental clearance, V 2 volume of peripheral compartment, BM 0 baseline VEGF165, k out elimination rate constant of VEGF165, K ss steady-state constant, RSE relative standard error, IIV inter-individual variability, CV coefficient of variation, bev bevacizumab